| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan 1, 2002 | In Use | ||
| NA | Trametinib | Mekinist | 2 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
| NA | Estradiol | Estrace | 2 mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
| J9092 | Cyclophosphamide | Cyclophosphamide | 2 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
| J9097 | Cyclophosphamide | Cyclophosphamide lyophilized | 2 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
| NA | Uridine Triacetate | Xuriden | 2 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
| C9024 | (Daunorubicin AND Cytarabine) Liposome | Vyxeos | 1mg/2.27mg | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | No | 2017 | In Use | |||
| Fruquintinib | Fruzaqla | 1mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2023 | In Use | ||||
| C9306 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | 2026 | Sep 8, 2025 | In Use | |
| J9063 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Jul 11, 2023 | In Use | ||
| J9258 | Paclitaxel (Teva) | Paclitaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2016 | Dec 7, 2023 | Sep 14, 2024 | No Longer Used | |
| C9080 | Melphalan flufenamide | Pepaxto | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | |
| J9228 | Ipilimumab | Yervoy | 1mg | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | No | 2011 | Jan 1, 2012 | In Use | ||
| C9240 | ixabepilone | Ixempra | 1mg | Chemotherapy | Antitumor Antibiotic | Epothilones | No | 2007 | Jan 1, 2008 | Dec 31, 2013 | No Longer Used | |
| J9358 | Fam-trastuzumab deruxtecan-nxki | Enhertu | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2, topoisomerase, tetrapeptide | No | 2019 | Jul 1, 2020 | In Use | ||
| J9354 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | Jan 1, 2014 | In Use | ||
| Q5136 | Denosumab-bbdz | Jubbonti/Wyost | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2024 | Sep 11, 2024 | In Use | ||
| J9326 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | Jan 1, 2026 | In Use | ||
| J9174 | Docetaxel (beizray) | Beizray | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2024 | Jul 9, 2025 | In Use | ||
| J9341 | Thiotepa (tepylute) | Tepylute | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2025 | Jul 9, 2025 | In Use | ||
| C9165 | Elranatamab-bcmm | Elrexfio | 1mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2023 | Dec 7, 2023 | Apr 17, 2024 | No Longer Used | |
| C9303 | Zolbetuximab-clzb | Vyloy | 1mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| NA | Anagrelide | Agrylin | 1mg | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Yes | 1997 | In Use | |||
| Q5159 | Denosumab-dssb | Ospomyv, Xbryk | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2025 | Sep 8, 2025 | In Use | ||
| J9057 | Copanlisib | Aliqopa | 1mg | Chemotherapy | Enzyme Inhibitor | PI3K | No | 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home